BiotechTube
Sirius Therapeutics

Sirius Therapeutics

San Diego, United States· Est.
siriusrna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Sirius Therapeutics is an innovative, privately-held biotech advancing a pipeline of siRNA therapies targeting major chronic diseases, with lead programs in Phase 2 and Phase 1/2a trials. The company has established a strong operational footprint in both the US and China, securing funding from top-tier investors like OrbiMed and forging a strategic collaboration with CRISPR Therapeutics. Its strategy is built on three 'mega-blockbuster' franchises in cardiovascular and metabolic diseases, supported by its proprietary PEPR siRNA technology platform.

CardiovascularMetabolic DiseaseCoagulation DisordersObesity

Technology Platform

Proprietary siRNA technology platform named PEPR, designed to develop novel RNAi therapeutics. Supports creation of therapies with potential improved potency, durability, and safety.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

Targeting massive chronic disease markets (cardiovascular, metabolic) where siRNA's durable effect could revolutionize long-term care.
The dual US-China operational model offers cost-efficient development and access to two major pharmaceutical markets.
Validation through the CRISPR Therapeutics collaboration could accelerate platform and pipeline expansion.

Risk Factors

High clinical development risk associated with lead siRNA candidates.
Intense competition in the RNAi space from established players like Alnylam and Arrowhead.
Execution risk in managing a complex dual-headquarters model and navigating two distinct regulatory pathways (FDA/NMPA).
Future funding needs are substantial to reach commercialization.

Competitive Landscape

Sirius operates in the competitive RNAi therapeutics arena, competing directly with leaders like Alnylam (approved products) and Arrowhead Pharmaceuticals. In cardiovascular/metabolic disease, it also faces competition from large pharma (Novo Nordisk, Amgen) and other modalities. Its differentiation hinges on its PEPR platform's performance and its strategy to efficiently develop drugs for global markets.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →